Mumbai: Earlier today, The Economic Times published a story in which a third of participants in an observational study discussed the side effects of Bharat Biotech’S covid-19 vaccine Covaxin gave information adverse events Special Interest (AESI), according to a report by SpringerLink.

According to the report, researchers found that adolescent girls and people with a history of allergies had a higher risk of AESI after taking Covaxin. Of the 1,024 individuals enrolled, 635 adolescents and 291 adults could be contacted during a one-year follow-up. According to the study, 304 (47.9 percent) adolescents and 124 (42.6 percent) adults reported viral infections in the upper respiratory tract.

Releasing a statement on the study, Bharat Biotech said, “To make such studies effective, informative and avoid investigator bias, the following data points are also required: AESI Safety of subjects before participating in the study Profile, comparison Comparison of the safety profile of unvaccinated subjects during the study, comparison of the safety profile of subjects who received other vaccines during the study.

It is further stated that all study participants should be followed throughout the study rather than just a subgroup. He said several studies on the safety of Covaxin have been conducted and published in peer-reviewed journals, demonstrating an excellent safety track record.

Recently, there has been a whirlwind of reports on several COVID-19 vaccines and their adverse events globally. AstraZeneca has acknowledged that its jab caused rare side effects and is withdrawing its vaccine worldwide. The company has already withdrawn its EU marketing authorization for the vaccine, which was branded Vaxzevira Manufactured in Europe and by Covishield in India Serum Institute of India (SII).

Today another report has come that the risk from AstraZeneca vaccine has increased Vaccine-induced immune thrombocytopenia and thrombosis (VITT), a rare but fatal blood clotting disorder. The research was conducted by Flinders University in Australia and other international experts. This report has been published in the New England Journal of Medicine. The report also has important implications for reform vaccine safety,

Another report titled ‘COVID-19: Two rare vaccine side effects found in large global study’, published in Vaccine, confirmed previously identified rare safety signals for myocarditis and pericarditis. mRNA vaccine (Pfizer and Moderna) and Guillain-Barré syndrome and cerebral venous sinus thrombosis (CVST) following viral vector vaccines (AstraZeneca).

These recent studies highlight the notable adverse events caused by COVID-19 vaccines globally, regardless of technology and manufacturer. Bharat Biotech has stressed the need for more comprehensive data to ensure unbiased and informed safety assessment. Rare side effects from the AstraZeneca vaccine and the mRNA vaccines from Moderna and Pfizer have been reported in several studies.

This underlines the ongoing need for rigorous security monitoring and transparent reporting. Ensuring the safety of not only COVID-19 vaccines, but every vaccine approved, is paramount, and continued research is critical to improving vaccine safety and public confidence. Manufacturers need to take patient safety as the top priority while developing vaccines.